Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_2
2
29%
Ph not_applicable
2
29%
Ph phase_3
1
14%
Ph phase_1
2
29%

Phase Distribution

2

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
1(14.3%)
N/ANon-phased studies
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Other(2)

Detailed Status

Completed5
unknown2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 22 (28.6%)
Phase 31 (14.3%)
N/A2 (28.6%)

Trials by Status

unknown229%
completed571%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis

NCT00075621
unknownphase_1

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

NCT02280993
completednot_applicable

Effects of Exercise in Combination With Epoetin Alfa

NCT00577096
completedphase_3

Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy

NCT02288741
completedphase_1

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

NCT00482846
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00075621Phase 2

Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis

Completed
NCT02280993Phase 1

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Unknown
NCT00577096Not Applicable

Effects of Exercise in Combination With Epoetin Alfa

Completed
NCT02288741Phase 3

Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy

Completed
NCT00482846Phase 1

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

Completed
NCT01723657Phase 2

Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)

Completed
NCT00006055Not Applicable

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

Unknown

All 7 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
7